Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 6OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Myeloid 2Plasma cell 1

Conditions

Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × itacitinib × 1 year × Clear all
NCT05364762 2026-06-03

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

City of Hope Medical Center

Phase 2 Active not recruiting
20 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT05660421 2026-04-27

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Vanderbilt-Ingram Cancer Center

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

NCT05757219 2026-03-31

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
27 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05823571 2025-09-18

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
32 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡